Latest News for: polyp
Edit
Polyps: Recommendations and Changes for a Better Life
The National Herald 15 Mar 2025
Intestinal polyps have become as common as ...
Edit
‘Tiny’ creature — with long polyps and tentacles — found near AL coast is new species
The Tribune San Luis Obispo 11 Mar 2025
“Even when we think we know everything, or that we think we have a grasp on what species occur in our environment, we don’t,” said Declan Morrissey, a zoologist at the Smithsonian ... .
Edit
New medication shows promise in treating chronic sinusitis with nasal polyps
China Daily 07 Mar 2025
Chronic sinusitis with nasal polyps (CRSwNP) accounts for 20 to 33 percent of these cases ... The report showed that treatment with Tezspire significantly reduced nasal polyp severity ... polyp patients.
Edit
Depemokimab delivers clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps (CRSwNP)
Pharmiweb 03 Mar 2025
Nasal polyp score (NPS, 0-8) at 52 weeks (treatment difference [95% CI], -0.7 [-0.9, -0.4], nominal p<0.001) ... Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE) ... Polyps (ANCHOR-1).
Edit
Depemokimab applications accepted for review by the US FDA for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps (CRSwNP)
Pharmiweb 03 Mar 2025
Both studies met their co-primary endpoints of change from baseline in total endoscopic nasal polyp score at 52 weeks and change from baseline in nasal obstruction verbal response scale (VRS) mean score from weeks 49 to 52.
Edit
Depemokimab delivers clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) (Form 6-K) (GSK plc)
Public Technologies 03 Mar 2025
Depemokimab delivers clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) ... Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE).
Edit
Depemokimab applications accepted for review by the US FDA for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps (CRSwNP) (GSK plc)
Public Technologies 03 Mar 2025
Both studies met their co-primary endpoints of change from baseline in total endoscopic nasal polyp score at 52 weeks and change from baseline in nasal obstruction verbal response scale (VRS) mean score from weeks 49 to 52.
Edit
Depemokimab applications accepted for review by the US FDA for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps (CRSwNP) (Form 6-K) (GSK plc)
Public Technologies 03 Mar 2025
Edit
Depemokimab delivers clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) (GSK plc)
Public Technologies 02 Mar 2025
) ANCHOR-1 and ANCHOR-2 phase III trials show improvements in nasal polyp size and ... Nasal polyp score (NPS, 0-8) at 52 weeks (treatment difference [95% CI], -0.7 [-0.9, -0.4], nominal p<0.001).
- 1